Background {#Sec1}
==========

Autonomic changes are evident from the onset of acute pathology requiring critical care. Cardiac autonomic function can be derived by analysing variability between heart beats to yield time domain and frequency domain (power spectral density) measures that reflect autonomic modulation of cardiac frequency \[[@CR1], [@CR2]\]. Heart rate variability (HRV) appears to contribute diagnostic and prognostic value in various cardiometabolic conditions associated with subclinical autonomic dysfunction that predispose to critical illness including hypertension, coronary artery disease, heart failure and diabetes \[[@CR3]--[@CR7]\]. Similarly, HRV has been proposed to serve as a potential diagnostic and prognostic tool in critically ill patients \[[@CR8]\].

However, HRV measures in critically ill patients are fraught with potential problems. \[[@CR9]\] Although population norms for HRV parameters have been reported in healthy populations \[[@CR10]\], the impact of multiple physiological, procedural and technical factors in critically ill patients has not undergone systematic scrutiny in critical care medicine \[[@CR11]\]. Moreover, the validity of HRV as a tool to interrogate autonomic function is increasingly under physiological scrutiny \[[@CR12], [@CR13]\], since a strong correlation between HRV and morbidity/mortality appears to be largely attributable to incident heart rate. In addition, recording technique, clinical context and adjustment for incident heart rate are key factors to consider when interpreting the translational relevance of HRV in critically ill patients.

Here, we sought to systematically evaluate the methodology and design of HRV studies in critical care medicine. We focused on whether recommended standards for measurement and reporting have been employed \[[@CR14], [@CR15]\], with the aim of identifying areas to refine in future HRV experimental design in critical care medicine.

Methods {#Sec2}
=======

Identification of studies {#Sec3}
-------------------------

A literature review was performed based on the Preferred Reporting Items for Systematic reviews and Meta-Analyses (PRISMA) guidelines for systematic reviews \[[@CR16]\]. The summary of the search strategy employed is shown in Additional file [1](#MOESM1){ref-type="media"}.

We searched the electronic databases PubMed, EMBASE, MEDLINE and the Cochrane Central Register of Controlled Clinical Trials for articles investigating HRV measurement in intensive care patients. Inclusion criteria were full-text studies written in English involving adult patients, published after 1996 (following published guidelines) and reporting traditional time and frequency domain parameters \[[@CR15]\]. Studies which reported newer analysis techniques of HRV (e.g. entropy analysis) were excluded, as we focussed on those reporting measures in line with recent European guidance \[[@CR17]\]. The following Medical Subject Headings (MESH) were used to identify pertinent articles: "Heart rate variability OR HRV AND Sepsis", "Heart rate variability OR HRV AND multiple organ dysfunction OR MODS", "Heart rate variability OR HRV AND critical illness", "Heart rate variability OR HRV AND intensive care OR ICU". The last search took place on 9 November 2016. We screened articles by title search and abstract review. Relevant articles were analysed for eligibility, and further articles were identified from reference lists. Articles were excluded based on the following criteria: experimental studies, incorrect target population (adult; \>18 years old), medical field other than intensive care, not original research, topic not within scope or traditional HRV parameters not reported.

Data extraction {#Sec4}
---------------

Data was extracted by two independent reviewers (S.K and A.S) and recorded into a standardised excel sheet recording: author, year of publication, study design, number of subjects, mean patient age, proportion of male subjects, risk stratification score, comparator groups, study aim and outcome, study design, protocol for measurement, processing, analysis and reporting of HRV parameters, adjustment and reporting of confounding factors and quality assessment. We identified the following clinical confounding factors: age, gender, average heart rate, average respiratory rate, co-morbidities, drugs, sedative drugs, vasoactive drugs, enteral nutrition and mechanical ventilation. Full details of the impact on HRV of these parameters are provided in Additional file [1](#MOESM1){ref-type="media"}. For reporting and analysis purposes, we selected the most commonly used time and frequency domain HRV parameters \[[@CR15]\].

Risk of bias and study quality assessment {#Sec5}
-----------------------------------------

The quality of studies was assessed by two assessors independently (SK, SM) using two established tools (Newcastle--Ottowa scale, Downs and Black Instrument). The Downs and Black instrument is recommended by the Cochrane Collaboration for use in non-randomised and observational studies (Additional file [1](#MOESM1){ref-type="media"}) \[[@CR18], [@CR19]\]. Inter-observer reliability evaluating quality within five domains: reporting, external validity, bias, confounding and power. Five questions were omitted because they are designed for interventional trials. The version which we employed in this study therefore has a maximum score of 22. Differences between reviewers were resolved by panel consensus opinion following further review of the article(s) in question by the senior author.

Results {#Sec6}
=======

Study selection {#Sec7}
---------------

We identified 238 studies which underwent screening by title search and abstract review. From these, 31 articles involving 2090 patients (including controls) met the inclusion criteria for assessing the role of HRV in critically ill patients \[[@CR20]--[@CR53]\]. Two articles analysed the same cohort of patients \[[@CR34], [@CR37]\].

Study characteristics {#Sec8}
---------------------

Demographic and clinical data, including comparator groups are summarised in Table [1](#Tab1){ref-type="table"}. All articles reported cohort or case--control studies. The average age of patients was 60 ± 7 years. The majority of studies (22/31; 71%) explored the association between HRV measures, morbidity and mortality. Key clinical findings from these studies are summarised in Table [2](#Tab2){ref-type="table"}. Due to significant differences in trial design, methodology, confounding, non-standardised comparator groups and inconsistent reporting of summary data, a meta-analysis could not be performed. However, there was consistency between studies in their findings that LF/HF ratio was inversely associated with increased disease severity or mortality. For illustrative purposes, the individual effect sizes across six studies reporting mean and standard deviation data looking at disease severity and mortality using the most commonly reported HRV parameter (LF/HF ratio) are shown (Fig. [1](#Fig1){ref-type="fig"}).Table 1Demographics and study design of studiesReference number. authorYearStudy designStudy populations (± comparator group)Patients (*n*)Age (mean ± SD or mean \[range\])Male (%)20. Annane1999Case--controlSepsis (healthy controls)26Septic shock 52 ± 14\
Sepsis 54 ± 17\
Control 43 ± 116521. Korach2001CohortSepsis4150 \[20--90\]4422. Barnaby2002CohortSepsis1559 \[39--85\]--23. Pontet2003Case--controlSepsis + MODS\
(Sepsis − MODS)22MODS 59.5 ± 17.8\
Non-MODS 60 ± 10.46424.Shen2003CohortWeaning24Successful wean 76 ± 12.9\
Unsuccessful wean 69.8 ± 17.84225. Schmidt2005CohortMODS\
(literature values)8560.4 ± 146226. Papaioannou2006CohortMODS5363.02 ± 14.685844. Bourgault2006CohortMixed aetiology1860 \[33--82\]7245. Chen2007CohortSepsis8167 \[30--84\]4150. Passariello2007Case--controlIschaemic sudden death40Sudden death 66 ± 8\
Pathology matched controls 68 ± 846. Chen2008CohortSepsis13267 \[27--86\]4747. Aboab2008Case--controlSepsis ± adrenal insufficiency\
(healthy controls)81Septic shock and adrenal failure 55 ± 16\
Septic shock 58 ± 19\
Healthy controls (not provided)3627. Nogueira2008CohortSepsis31Survivors 44.9 ± 5.9\
Non-survivors 55.6 ± 4.637428. Papaioannou2009CohortSepsis\
(Sepsis SOFA \<10)4557.8--51. Tiainen2009CohortOut of hospital cardiac arrest70Hypothermia 60 (23--75)\
Normothermia 59 (18--75)8629. Schmidt2010Case--control^a^MODS17861.1 ± 13.26730. Kasaoka2010CohortSIRS1053 ± 157031. Chen2012Case--controlSepsis and out of hospital cardiac arrest\
(Non-severe sepsis and healthy controls)210Out of hospital cardiac arrest 68 ± 10\
Severe sepsis and mechanical ventilation 66 ± 8\
Severe sepsis 68 ± 7\
Sepsis 67 ± 6\
Healthy 66 ± 65532.Gomez Duque2012CohortSepsis\
(literature values)10055 \[18--88\]4233. Brown2013CohortSepsis4857 \[40--63\]4634. Green2013CohortMODS3356.5 ± 15.96135.Wieske2013CohortICU acquired weakness83ICU acquired weakness 60 ± 13\
No ICU acquired weakness 59 ± 166036. Wieske2013CohortMixed aetiology\
(healthy controls)32Patients 54 ± 15\
Healthy control 36 ± 27037. Bradley2013CohortMixed aetiology3356.5 ± 15.96138. Huang2014CohortMixed aetiology101Successful 65 ± 18\
Unsuccessful 71 ± 166539. Zhang2014CohortSIRS/MODS\
(non-MODS)4147 \[34--59\]5440. Schmidt2014Case--control^a^CCF and MODS\
(literature values)130CCF 63 ± 10.1\
MODS 62.8 ± 10.26352. Tang2014Case--controlStroke227AF stroke 74 ± 12\
Non-AF stroke 62 ± 15\
Age/sex-matched controls 61 ± 104041. Zaal2015Case--controlICU delirium\
(no delirium)25ICU delirium 67 ± 12\
No ICU delirium 57 ± 167242. Hammash2015CohortWeaning3553.3 ± 14.66653. Nagaraj2016Case series^a^Not specified4056.3 ± 16.862.5Reference for each paper is shown before first author (first column)*CCF* congestive cardiac failure, *MODS* multiple organ dysfunction syndrome, *SIRS* systemic inflammatory response syndrome, *SOFA* sequential organ failure assessment^a^Retrospective analysis Table 2Study objectives and key findingsAuthorYearStudy objectivesKey findingsAnnane1999Compare HRV between sepsis, septic shock and healthy volunteersTP, LF, LFnu, LF/HF lower in septic shock vs sepsisKorach2001Effects of sepsis, age, sedation, catecholamines and illness severity on sympathovagal balance (LF/HF)LF/HF ratio \<1.5 was associated with sepsis and mortalityBarnaby2002Assess if HRV can predict sepsis severityNegative correlation between LFnu, LF/HF and SOFA scorePontet2003Assess if HRV can predict MODS in sepsisLow LF and RMSSD associated with MODSShen2003Assess changes in cardiac autonomic activity during weaning from mechanical ventilationHF, LF and TP decreased in unsuccessful group during spontaneous breathing trialSchmidt2005Effects of MODS, age, sedation, catecholamines, mechanical ventilation on HRV\
Assess if HRV can predict mortality in MODSTime and frequency domain reduced in MODS\
HRV indices affected by mechanical ventilation but not age, sedation or catecholamines\
LnVLF associated with 28-day survival.Papaioannou2006Assess if HRV associated with disease severity and mortalityLF/HF ratio negatively correlated with SOFA scoreBourgault2006Effects of endotracheal suction on HRVNo significant differences found in HRV indices between closed or open suctioningChen2007Assess if HRV can predict sepsis severitySeptic shock associated lower LF, LFnu, LF/HF, and higher RMSSD, HF, HFnuPassariello2007Assess if HRV can predict ischaemic sudden cardiac deathSDNN decreases shortly before ischaemic sudden deathChen2008Assess if HRV can predict 28-day mortalityLow SDNN, TP, VLF, LF and LF/HF associated with increased 28-day mortalityAboab2008Assess effect of steroids on HRV in patients with sepsisLF, LFnu, LF/HF lower in septic shock. Corticosteroids helped increase LFnu values in adrenal insufficiency group.Nogueira2008Assess relationship between HRV, markers of myocardial damage and free fatty acids in sepsisLow LF, HF and LF/HF associated with mortalityPapaioannou2009Assess relationship between HRV and biomarkers of inflammation (CRP, IL-6, IL-10) in patients with sepsisThere is a negative correlation between LFnu, LF/HF and CRP, IL-6, IL-10, SOFA scoreTiainen2009Assess if HRV changes (and has prognostic ability) with therapeutic cooling of resuscitated cardiac arrest patientsHigher SDNN, SDANN, TP, LF, HF in the first 48 h of cooling. SDNN \>100 ms predicts better neurological outcomeSchmidt2010To assess if ACE-I therapy affects short (28-day) and long (365-day) mortality in patients with MODSACE-I associated with preserved VLF, LF, HF, TP and survival (28-day and 365-day)Kasaoka2010To trial a real-time HRV measurement and analysis systemLF, HF and LF/HF higher in patients spontaneously breathing compared to mechanical ventilationChen2012To compare HRV between post-resuscitation cardiac arrest patients and patients with severe sepsisNo significant differences in HRV indices between OOHCA and Severe Sepsis patients\
Low LF, LFnu, LF/HF associated with mortalityGomez Duque2012To investigate the incidence of cardiovascular adverse events in patients with sepsisDeceased patients demonstrated lower SDNN than survivorsBrown2013Assess if HRV can predict vasopressor dependence at 24 h in sepsisTraditional HRV indices not associated with vasopressor requirement after controlling for HRGreen2013Association of HRV and illness severity in MODSLow LFnu and LF/HF associated with increased MODSWieske2013Relationship between autonomic dysfunction (HRV) and ICU-acquired weaknessArtefacts, mechanical ventilation, sedation, catecholamines and heart rate all associated with TP\
% artefacts were associated with TP and LF/HF\
No association between HRV and ICU-acquired weaknessWieske2013Compare different autonomic function tests in critically unwell patients (CFT, SWT and HRV)Only HRV tests associated with SOFA scoreBradley2013Impact of sedation and sedation interruptions on HRVSDNN, RMSSD and HF all increased during sedation interruption (more pronounced in less unwell patients)Huang2014Assess if HRV associated with weaning success or failureReduction in TP during SBT associated with failureTang2014Assess if HRV predicts outcome in ICU stroke patientsTraditional HRV indices were unable to predict outcomeZhang2014Asses if HRV can predict infected pancreatic necrosis or MODS in patients with severe acute pancreatitisLow LFnu, LF/HF and high HFnu associated with increased MODS and mortalitySchmidt2014Assess relationship between HRV and illness severity in CCF and MODSMODS patients demonstrated lower HRV indices in all parameters compared to CCF patients.Zaal2015To assess if HRV is abnormal in patients with ICU delirium.No association between HRV and delirium foundHammash2015Assess relationship between HRV and incidence of dysrhythmias during weaningLF was higher during spontaneous breathing than during controlled mechanical ventilation.Nagaraj2016Assess if sedation levels can be classified by HRV algorithmsAlgorithms using composite measures of HRV may discriminate between levels of sedation in ICU patients*ACE-I* angiotensin-converting enzyme inhibitor, *CCF* congestive cardiac failure, *CFT* cold face test, *CRP* C-reactive protein, *HF* high frequency, *HFnu* high frequency normalised unit, *HRV* heart rate variability, *IL-6* interleukin 6, *IL-10* interleukin 10, *LF* low frequency, *LFnu* low frequency normalised unit, *MODS* multiple organ dysfunction, *RMSSD* root mean square of successive differences, *SOFA* sequential organ failure assessment, *SBT* spontaneous breathing trial, *SWT* skin wrinkle test, *TP* total power, *VLF* very low frequency, *LnVLF* natural logarithm of very low frequency Fig. 1Forest plot of individual effect sizes (Cohen's *d*) across six studies investigating the relationship between LF/HF ratio and disease severity and mortality

Quality of studies {#Sec9}
------------------

No studies reported Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) guidelines. Two studies analysed data retrospectively. A minority of studies (*n* = 5; 16%) used individualised HRV data---i.e. patients serving as their own control, prior to an intervention. More than one third of studies (*n* = 13; 42%) did not describe any comparator group. The remainder of studies used non-age matched healthy volunteers, non-critically ill patients with established cardiovascular disease or HRV values derived from the literature. External validity (as adjudged by the Down and Black assessment tool) was poor, with the majority of studies achieving a score of 1.

Risk of bias assessment {#Sec10}
-----------------------

We found recurring potential sources of bias in study design, with 19 (61%) studies failing to report whether HRV data analysers were masked to the patient condition/outcome (Additional file [1](#MOESM1){ref-type="media"}). Only one study performed a power calculation \[[@CR41]\].

Data acquisition and preparation {#Sec11}
--------------------------------

Details on short-term recordings, including source of heart rate periods \[[@CR54], [@CR55]\], duration of recordings, epochs used for analysis and patient position \[[@CR56]\] were variable or not reported. Fourteen (45%) studies did not describe the sampling frequency of recordings; four (13%) studies used sampling rates below the recommended 250 Hz \[[@CR15]\].

ECG recording in the critically ill population is frequently contaminated by electrical and physiological artefacts. Thus, detailing methods to detect artefact (manual or automated) and its management (segment selection, deletion or interpolation) is important for data interpretation \[[@CR57]\]. Fourteen (45%) studies reported automated and/or manual editing of the raw ECG to remove artefact by replacing the missing data with cubic spline or linear interpolation methods. In keeping with guidelines, the majority of studies used interpolation methods as opposed to deletion of abnormal beats to avoid a loss of information \[[@CR15]\].

HRV analysis {#Sec12}
------------

Measurement protocols, processing and reporting of HRV data are summarised in Table [3](#Tab3){ref-type="table"}.Table 3Procedures for measurement, processing and reporting of HRVAuthorYearRecording protocol (duration/position/time)MonitorSampling frequency (Hz)Management of artefactData presentedAnnane19995 min/--/--PRV500InterpolationTP, LF, HF, LF/HF, Lfnu, HfnuKorach200130 min supine/0800--1200ECG5InterpolationLfnu, Hfnu, LF/HFBarnaby20025 min/--/--ECG--InterpolationTP, LF, HF, Lfnu, Hfnu, LF/HFPontet200310 min/supine/2100--2300ECG\>500InterpolationSDNN, RMSSD, LF, HF, Lfnu, Hfnu, LF/HFShen200390 min/semi recumbent/1000--1400ECG--InterpolationTP, LnLF, LnHF, Lfnu, Hfnu, LF/HFSchmidt200524 hoursECG256InterpolationSDNN, SDANN, RMSSD, pNN50, VLF, LF, HF, LF/HFPapaioannou200610 min/supine/morningECG250Segment selectionLF/HFBourgault200620 min/--/day and nightECG1000--LF, HF, LF/HF, TPChen200710 min/supine/day and nightECG--InterpolationRMSSD, TP, LF, HF, Lfnu, Hfnu, LF/HFPassariello200724 hECG----SDNN, SDANN, pNN50, RMSSDChen200810 min/supine/day and nightECG--InterpolationSDNN, RMSSD, TP, LF, HF, Lfnu, Hfnu, LF/HFAboab20085 min/supine/--PRV--InterpolationTP, Lfnu, Hfnu, LF/HFNogueira200830 min/supine/morningECG----LF, HF, LF/HFPapaioannou200910 min/--/--ECG250Segment selectionSDNN, Lfnu, Hfnu, LF/HFTiainen200924 hECG----SDNN, SDANN, TP, LF, HF,Schmidt201024 hECG256InterpolationLnTP, LnVLF, LnHF, LnLF, LF/HFKasaoka20105 min/supine/--ECG----LnLF, LnHF, LF/HFChen201210 min/supine/day and nightECG--InterpolationSDNN, TP, VLF, LF, HF, Hfnu, Lfnu, LF/HFGomez Duque201224 hECG----SDNN, PNN50Brown20136 h/--/--ECG500DeletionSDNN, pNN50, Lfnu, Hfnu, LF/HFGreen201324 hECG125DeletionSDNN, RMSSD, Lfnu, Hfnu, LF/HFWieske20135 min/--/--ECG250InterpolationHR, TP, LF/HFWieske20135 min/supine/--ECG250DeletionLF, HF, Lfnu, Hfnu, LF/HFBradley201324 hECG125DeletionSDNN, RMSSD, LF, HF, LF/HFHuang20145 min/semi-recumbent/0800--1200ECG----LnTP, LnVLF, Hfnu, Lfnu, LF/HFTang201460 min/--/--ECH512--SDNN, RMSSD, LF, HF, LF/HFZhang20145 min/--/0900--1100ECG--DeletionSDNN, RMSSD, TP, VLF, LF, HF, Lfnu, Hfnu, LF/HFSchmidt201424 hECG256InterpolationSDNN, SDANN, SDNNi, RMSSD, pNN50, VLF, LF, HF, LnLF, LnHF, LF/HFZaal201515 min/supine, 0800--1700ECG500Segment selectionLnLF, LnHF, Hfnu, LF/HFHammash201524 hECG--InterpolationVLF, HF, LFNagaraj201624 h (5 min epochs)ECG240ThresholdingSDNN, RMSSD, VLF, LF, HF, LF/HF, LFnu, HFnu*ECG* electrocardiogram, *HF* high frequency, *HFnu* high frequency normalised unit, *LF* low frequency, *LFnu* low frequency normalised unit, *Ln* natural logarithm, *pNN50* percentage of normal--normal intervals \>50 ms, *PRV* pulse rate variability, *RMSSD* root mean square of successive differences, *SDANN* standard deviation of average normal--normal intervals, *SDNN* standard deviation of normal--normal intervals, *TP* total power

A minority of studies (14; 45%) reported both frequency and time domain data (Table [3](#Tab3){ref-type="table"}). A minority of studies (9; 29%) reported frequency data in normalised units together with absolute values, in keeping with established recommendations. Summary values for commonly reported HRV parameters revealed a wide range of non-normally distributed data for each (Additional file [1](#MOESM1){ref-type="media"}: Table S3). Reporting and/or adjustment for heart rate and respiratory rate, which dramatically alter both high and low frequency spectral components \[[@CR58]\] was inconsistent between studies. A small majority of studies (17; 55%) reported average heart rate, whilst a minority (6; 19%) adjusted for, or reported, respiratory rate during data acquisition.

Pharmacologic and clinical interventions {#Sec13}
----------------------------------------

Studies varied in their exclusion criteria and reporting of potential confounding factors including age, gender, body mass index \[[@CR59]\], common comorbidities \[[@CR60]--[@CR63]\], drug therapy \[[@CR64]--[@CR68]\] and/or ICU interventions (Tables [4](#Tab4){ref-type="table"} and [5](#Tab5){ref-type="table"}). Exclusion criteria used and comorbidities/drugs are summarised in Additional file [1](#MOESM1){ref-type="media"}. A minority of studies (12; 39%) excluded patients with chronic comorbidities that are commonly associated with autonomic dysfunction. Reporting of drugs that directly affect autonomic function was highly variable across studies. A majority of studies (25; 81%) did not detail drug therapy. Around 22% studies did not report the use of mechanical ventilation, and more than 25% failed to report whether sedation and/or vasoactive drugs were used at the time of HRV recordings.Table 4Reporting of potential clinical confoundersAuthorYearComorbiditiesDrugsMechanical ventilation (% patients)Sedation (% patients)Catecholamines (% patients)FeedingHR/RR reportedAnnane1999Excluded--100%0%0%--HR/RRKorach2001----41.5%.19.5%12.20%----Barnaby2002----0%--0%--HR/RRPontet2003ExcludedExcluded38.5%--17.90%--HRShen2003++100%0%0%--HR/RRSchmidt2005----71%61%62%----Papaioannou2006+----+------Bourgault2006ExcludedExcluded100%33%0%--HRChen2007Excluded/+------0%--HR/RRPassriello2007++--------HRChen2008+--0%------HRAboab2008Excluded--100%80.9%100%--HRNogueira2008Excluded--100%--100%--RRPapaioannou2009--Excluded100%100%------Tiainen2009+--100%100%87%--HRSchmidt 02010+--88%89%74%----Kasaoka 12010----100%100%------Chen2012+--OHCA 100%, SS + MV 100%, SS 0%, S 0%OHCA 81, SS + MV 63%, SS 59%, S 0%OHCA 100%, SS + MV 9%, SS 18.8%, S 0%--HRGomez Duque2012Excluded/+------72%----Brown2013--------63%--HRGreen2013----90.90%+78.80%--HRWieske2013Excluded/+++++--HRWieske2013Excluded/+--100%--------Bradley2013----+++--HRHuang2014Excluded/+Excluded/+100%------RRZhang2014--------12%----Schmidt2014--+89.2%72.3%72.3%--HRTang2014++--------HRZaal2015ExcludedExcluded60%20%0%----Hammash2015Excluded/+--100%--------Nagaraj2016----100%100%----HRExcluded refers to specific comorbidities or drugs were part of exclusion criteria of study*HR* heart rate, *RR* respiratory rate, *+* reported but proportion of patients not provided, *--* not reported Table 5Reporting of potential confoundersAuthorYearComorbiditiesDrugsMechanical ventilation (% patients)Sedation (% patients)Catecholamines (% patients)FeedingHR/RR reportedAnnane \[[@CR17]\]1999Excluded--100%0%0%--HR/RRKorach \[[@CR18]\]2001----41.5%.19.5%12.20%----Barnaby \[[@CR19]\]2002----0%--0%--HR/RRPontet \[[@CR20]\]2003ExcludedExcluded38.5%--17.90%--HRShen \[[@CR21]\]2003++100%0%0%--HR/RRSchmidt \[[@CR22]\]2005----71%61%62%----Papaioannou \[[@CR23]\]2006+----+------Bourgault \[[@CR24]\]2006ExcludedExcluded100%33%0%--HRChen \[[@CR25]\]2007Excluded/+------0%--HR/RRPassriello2007++--------HRChen \[[@CR26]\]2008+--0%------HRAboab \[[@CR27]\]2008Excluded--100%80.9%100%--HRNogueira \[[@CR28]\]2008Excluded--100%--100%--RRPapaioannou \[[@CR29]\]2009--Excluded100%100%------Tiainen2009+--100%100%87%--HRSchmidt \[[@CR30]\]2010+--88%89%74%----Kasaoka \[[@CR31]\]2010----100%100%------Chen \[[@CR32]\]2012+--OHCA 100%, SS + MV 100%, SS 0%, S 0%OHCA 81, SS + MV 63%, SS 59%, S 0%OHCA 100%, SS + MV 9%, SS 18.8%, S 0%--HRGomez Duque \[[@CR33]\]2012Excluded/+------72%----Brown \[[@CR34]\]2013--------63%--HRGreen \[[@CR35]\]2013----90.90%+78.80%--HRWieske \[[@CR36]\]2013Excluded/+++++--HRWieske \[[@CR37]\]2013Excluded/+--100%--------Bradley \[[@CR38]\]2013----+++--HRHuang \[[@CR39]\]2014Excluded/+Excluded/+100%------RRZhang \[[@CR40]\]2014--------12%----Schmidt \[[@CR41]\]2014--+89.2%72.3%72.3%--HRTang2014++--------HRZaal \[[@CR42]\]2015ExcludedExcluded60%20%0%----Hammash \[[@CR43]\]2015Excluded/+--100%--------Nagaraj2016----100%100%----HRExcluded refers to specific comorbidities or drugs were part of exclusion criteria of study*HR* heart rate, *RR* respiratory rate, + reported but proportion of patients not provided, -- not reported

Discussion {#Sec14}
==========

This review is the first to systematically explore how HRV analyses are undertaken and/or reported in critically ill patients. Despite a wealth of laboratory and translational data suggesting that HRV may offer diagnostic and prognostic utility, significant heterogeneity in methodology between HRV articles precluded comparisons across studies and meta-analysis. Our review identifies several areas that require greater scrutiny in future, highlighting the need to develop consensus guidelines that are relevant and tailor-made for the challenges faced by researchers in critical care medicine.

Well-recognised technical, physiologic and clinical factors impact on the measurement, and interpretation of HRV \[[@CR69], [@CR70]\]. We found highly variable practice in three key technical areas. Low sampling rates (\<250 Hz) impair the precise detection of the R wave fiducial point in the ECG waveform, which consequently affects the power spectrum \[[@CR15]\]. This is particularly relevant for studies that derived R--R intervals from arterial pressure waveform analysis \[[@CR20], [@CR47]\], since non-neural respiratory influences (e.g. changes in ventricular mechanics) differentially affect mechanical pulse waves and electrical R waves \[[@CR55]\]. Manual inspection of the raw ECG to identify artefact is preferred to automated methods to avoid the introduction of false frequency components into the power spectrum \[[@CR57]\]. The variable (or unstated) masking of HRV analysers to clinical data also introduces potential significant bias.

From a physiologic perspective, reporting and/or adjustment for heart rate and respiratory rate was inconsistent between studies, with heart rate frequently not reported. Across species with highly variable heart rates, HRV appears to be largely attributable to incident heart rate. If heart rate is not taken into account, erroneous conclusions regarding HRV are likely since differences may merely reflect lower heart rate \[[@CR12]\]. This is particularly of relevance to hemodynamically unstable critically ill patients, in whom heart rate may rapidly change. Similarly, increases in respiratory frequency and tidal volume affect both high and low frequency spectral components \[[@CR58]\]. Hence, standardised criteria for ventilatory and heart rate reporting are required for the interpretation of HRV data between studies (and hence, potentially, meta-analysis).

From a clinical perspective, HRV parameters are influenced strongly by age, gender, functional capacity and chronic comorbidities. Whilst all studies estimated severity of illness, the most frequently employed---Acute Physiology and Chronic Health Evaluation II (APACHE-II)---are limited in capturing information about chronic comorbid disease that are over-represented in the critical care medicine population. For example, diabetes mellitus, a common condition associated with cardiac autonomic neuropathy, is not captured by this type of assessment \[[@CR60]\]. Typically, chronic conditions at the severe end of the disease spectrum are included (e.g. APACHE-II score only includes severe heart failure (≥NYHA class 3). However, HRV parameters have been found to be abnormal in early cases of chronic disease, including preserved ejection fraction, coronary artery disease, chronic kidney disease and hypertension \[[@CR60]--[@CR63]\]. Although some studies have considered these factors, serial measures or dynamic autonomic challenges offer a potentially more insightful and individualised approach to assessing HRV. Novel HRV parameters that can be captured within the first few minutes of critical illness, such as deceleration capacity of heart rate \[[@CR71]\], may mitigate the need for refining the use of more traditional time and frequency domain measures. For mechanistic studies investigating whether changes in autonomic parameters correlate with, or precede, pathologic events, targeting clinical scenarios where multiple, complementary baseline autonomic measures \[[@CR72], [@CR73]\] can be made before critical illness develops may be optimal \[[@CR74]\]. Studies where basal autonomic function can be captured, including elective surgery \[[@CR73]--[@CR76]\] and oncologic sepsis \[[@CR48], [@CR49]\], may provide particularly powerful mechanistic insights since autonomic changes can be individualised and referenced to pre-insult normal, or pre-existing, dysfunction. Several studies have highlighted that HRV values in critical care medicine are similar to those found in common cardiovascular pathologic conditions \[[@CR74], [@CR75], [@CR77]\]; this highlights the need for individualised patient data in order to rule out that autonomic dysfunction is not a precursor of critical illness, rather than merely a biomarker.

Commonly used anti-arrhythmic drugs, anti-hypertensive drugs, statins, metformin and inhaled bronchodilators have all been associated with changes in HRV parameters \[[@CR60]--[@CR63]\]. However, the lack of reporting on medications that critically ill patients received reduces the mechanistic insight afforded by this approach, particularly given the strong correlation between HRV and morbidity/mortality appears to be largely attributable to incident heart rate. Similarly, the majority of studies in this review failed to consistently report on the use of common critical care interventions. This may explain why conflicting conclusions over how variety of features of critical illness may affect HRV. Continuous enteral or parenteral nutrition are both associated with a reduction in time domain HRV measures indicative of parasympathetic cardiac modulation \[[@CR67]\]. However, we did not find any studies that reported on the feeding or fasting status of patients. Although a significant limitation of our study was the lack of primary source data, in any event, we could not identify a single common HRV parameter measured in all studies that enabled comparison. A further limitation is that we did not consider newer nonlinear and multiscale approaches, since very few studies incorporating these analyses have been undertaken. These approaches are also likely to be affected by the same factors that influence traditional HRV parameters \[[@CR78]\]. Thus, in a clinical setting, further work is required to establish whether these newer approaches reduce the impact of several confounding factors we have identified in this review.

Conclusions {#Sec15}
===========

Heart rate and derived heart rate variability offers a non-invasive, inexpensive tool that may add mechanistic insights to our understanding of critical illness and also assist clinical care. However, the current interpretation of generalizable and clinically relevant values to aid clinical decisions/research is hampered by a non-standardised methodologic approach and lack of adjustment for important confounding factors. For critical care medicine to exploit recent advances in translational autonomic physiology, further high-quality prospective HRV studies underpinned by the development of consensus reporting standards relevant for critical care medicine are needed.
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Additional file 1:Clinical confounding factors. (DOCX 34 kb)

HRV

:   Heart rate variability

APACHE-II

:   Acute Physiology and Chronic Health Evaluation II

NYHA

:   New York Heart Association

ECG

:   Electrocardiogram

MODS

:   Multiple organ dysfunction syndrome
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